Cargando…
Patient and public involvement in the benefit–risk assessment and decision concerning health products: position of the Scientific Advisory Board of the French National Agency for Medicines and Health Products Safety (ANSM)
| Autores principales: | , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BMJ Publishing Group
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10201242/ https://www.ncbi.nlm.nih.gov/pubmed/37208125 http://dx.doi.org/10.1136/bmjgh-2023-011966 |
| _version_ | 1785045225243148288 |
|---|---|
| author | Belgodère, Laëtitia Pougheon Bertrand, Dominique Jaulent, Marie Christine Rabeharisoa, Vololona Janssens, Walter Rollason, Victoria Barbot, Janine Vernant, Jean Paul Oualikene Gonin, Wahiba Maison, Patrick Ankri, Joel |
| author_facet | Belgodère, Laëtitia Pougheon Bertrand, Dominique Jaulent, Marie Christine Rabeharisoa, Vololona Janssens, Walter Rollason, Victoria Barbot, Janine Vernant, Jean Paul Oualikene Gonin, Wahiba Maison, Patrick Ankri, Joel |
| author_sort | Belgodère, Laëtitia |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10201242 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | BMJ Publishing Group |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-102012422023-05-23 Patient and public involvement in the benefit–risk assessment and decision concerning health products: position of the Scientific Advisory Board of the French National Agency for Medicines and Health Products Safety (ANSM) Belgodère, Laëtitia Pougheon Bertrand, Dominique Jaulent, Marie Christine Rabeharisoa, Vololona Janssens, Walter Rollason, Victoria Barbot, Janine Vernant, Jean Paul Oualikene Gonin, Wahiba Maison, Patrick Ankri, Joel BMJ Glob Health Commentary BMJ Publishing Group 2023-05-19 /pmc/articles/PMC10201242/ /pubmed/37208125 http://dx.doi.org/10.1136/bmjgh-2023-011966 Text en © Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) . |
| spellingShingle | Commentary Belgodère, Laëtitia Pougheon Bertrand, Dominique Jaulent, Marie Christine Rabeharisoa, Vololona Janssens, Walter Rollason, Victoria Barbot, Janine Vernant, Jean Paul Oualikene Gonin, Wahiba Maison, Patrick Ankri, Joel Patient and public involvement in the benefit–risk assessment and decision concerning health products: position of the Scientific Advisory Board of the French National Agency for Medicines and Health Products Safety (ANSM) |
| title | Patient and public involvement in the benefit–risk assessment and decision concerning health products: position of the Scientific Advisory Board of the French National Agency for Medicines and Health Products Safety (ANSM) |
| title_full | Patient and public involvement in the benefit–risk assessment and decision concerning health products: position of the Scientific Advisory Board of the French National Agency for Medicines and Health Products Safety (ANSM) |
| title_fullStr | Patient and public involvement in the benefit–risk assessment and decision concerning health products: position of the Scientific Advisory Board of the French National Agency for Medicines and Health Products Safety (ANSM) |
| title_full_unstemmed | Patient and public involvement in the benefit–risk assessment and decision concerning health products: position of the Scientific Advisory Board of the French National Agency for Medicines and Health Products Safety (ANSM) |
| title_short | Patient and public involvement in the benefit–risk assessment and decision concerning health products: position of the Scientific Advisory Board of the French National Agency for Medicines and Health Products Safety (ANSM) |
| title_sort | patient and public involvement in the benefit–risk assessment and decision concerning health products: position of the scientific advisory board of the french national agency for medicines and health products safety (ansm) |
| topic | Commentary |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10201242/ https://www.ncbi.nlm.nih.gov/pubmed/37208125 http://dx.doi.org/10.1136/bmjgh-2023-011966 |
| work_keys_str_mv | AT belgoderelaetitia patientandpublicinvolvementinthebenefitriskassessmentanddecisionconcerninghealthproductspositionofthescientificadvisoryboardofthefrenchnationalagencyformedicinesandhealthproductssafetyansm AT pougheonbertranddominique patientandpublicinvolvementinthebenefitriskassessmentanddecisionconcerninghealthproductspositionofthescientificadvisoryboardofthefrenchnationalagencyformedicinesandhealthproductssafetyansm AT jaulentmariechristine patientandpublicinvolvementinthebenefitriskassessmentanddecisionconcerninghealthproductspositionofthescientificadvisoryboardofthefrenchnationalagencyformedicinesandhealthproductssafetyansm AT rabeharisoavololona patientandpublicinvolvementinthebenefitriskassessmentanddecisionconcerninghealthproductspositionofthescientificadvisoryboardofthefrenchnationalagencyformedicinesandhealthproductssafetyansm AT janssenswalter patientandpublicinvolvementinthebenefitriskassessmentanddecisionconcerninghealthproductspositionofthescientificadvisoryboardofthefrenchnationalagencyformedicinesandhealthproductssafetyansm AT rollasonvictoria patientandpublicinvolvementinthebenefitriskassessmentanddecisionconcerninghealthproductspositionofthescientificadvisoryboardofthefrenchnationalagencyformedicinesandhealthproductssafetyansm AT barbotjanine patientandpublicinvolvementinthebenefitriskassessmentanddecisionconcerninghealthproductspositionofthescientificadvisoryboardofthefrenchnationalagencyformedicinesandhealthproductssafetyansm AT vernantjeanpaul patientandpublicinvolvementinthebenefitriskassessmentanddecisionconcerninghealthproductspositionofthescientificadvisoryboardofthefrenchnationalagencyformedicinesandhealthproductssafetyansm AT oualikenegoninwahiba patientandpublicinvolvementinthebenefitriskassessmentanddecisionconcerninghealthproductspositionofthescientificadvisoryboardofthefrenchnationalagencyformedicinesandhealthproductssafetyansm AT maisonpatrick patientandpublicinvolvementinthebenefitriskassessmentanddecisionconcerninghealthproductspositionofthescientificadvisoryboardofthefrenchnationalagencyformedicinesandhealthproductssafetyansm AT ankrijoel patientandpublicinvolvementinthebenefitriskassessmentanddecisionconcerninghealthproductspositionofthescientificadvisoryboardofthefrenchnationalagencyformedicinesandhealthproductssafetyansm AT patientandpublicinvolvementinthebenefitriskassessmentanddecisionconcerninghealthproductspositionofthescientificadvisoryboardofthefrenchnationalagencyformedicinesandhealthproductssafetyansm |